US Transdermal Patch Market & Clinical Trial Insight - Single/Multiple-Layer Drug-in-Adhesive / Reservoir Transdermal / Matrix Based Transdermal / Vapor / Active and Passive Patches

Dublin, Jan. 19, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/gd992k/us_transdermal) has announced the addition of the "US Transdermal Patch Market & Clinical Trial Insight" report to their offering.

Innovations in pharmaceutical industry have a long track record of showing commercialization potential with respect to emerging and feasible technology. In US, such innovations have high level of acceptance among various stake holders of the pharmaceutical industry. Transdermal patches have emerged as one such innovations which have rich history but main development has been observed in past decade. They have been improved from a mere piece of tape dipped in formulation to complex matrix system containing therapeutics offering higher control over drug delivery. Long-term usage, high cost-effectiveness, high compliance rates and easy availability are some of the major factors behind the growth of transdermal patches in US.

Consumer base for transdermal patches is quite high in US in comparison to other markets across the globe. Segments like female contraceptives and Nicotine Replacement Therapy (NRT) have received lots of attention in past years. Indications like Parkinson's disease and Alzheimer's disease have few transdermal patches and have unexplored opportunities in US market. While Insulin and vaccine patches are at different stages of clinical trials which would be introduced in coming years. Unexplored disease segments have less competition and lack of transdermal patches makes them suitable choice for potential transdermal patch developers. This scenario suggests that US transdermal patch market has lots of commercialization opportunities that have to be reaped in coming years.

Some of the transdermal patches have completed their product life cycle and have given way to generic transdermal patches. Several small/mid-sized transdermal patch developers can take benefit of this scenario. Side-by-side, transdermal manufacturers have developed capabilities to customize products according to client's necessities. Improvement of transdermal patch technology is also expected to place as material science and associated fields are also developing. These observations suggest that US transdermal patch market will offer several commercialization opportunities. In this way, US transdermal patch segment shows progress at every level reflecting that this segment is expected to grow several folds in coming years.

US Transdermal Patch Market & Clinical Trial Insight Report Highlights:

- US Transdermal Patch Market Overview
- Generic & Branded Transdermal Patches
- US Transdermal Patch Market: Value Chain Analysis
- US Transdermal Patch Contract Manufacturing Organization
- US Transdermal Patch Clinical Pipeline Insight by Company, Indication & Phase
- US Transdermal Patch Clinical Pipeline: 55 Patches
- Majority Patches in Preclinical Phase: 27 Patches
- Marketed Transdermal Patch Clinical Insight by Company & Indication
- Marketed Transdermal Patches in US: 33 Patches

Key Topics Covered:

1. Introduction to Transdermal Patch

2. Types of Transdermal Patches

3. Mechanism of Transdermal Patch Drug Delivery

4. Advantages of Transdermal Patch

5. US Transdermal Patch Market Overview

6. Generic & Branded Transdermal Patches

7. US Transdermal Patch Market: Value Chain Analysis

8. US Transdermal Patch Contract Manufacturing Organization (CMO)

9. US Transdermal Patch Market Growth Frontiers

10. US Transdermal Patch Market Landscape

11. US Transdermal Patch Market Future Prospects

12. US Transdermal Patch Clinical Pipeline Insight by Company,Indication & Phase

13. Marketed Transdermal Patch Clinical Insight by Company & Indication

14. Discontinued & Suspended Transdermal Patch Clinical Insight by Company, Indication & Phase

15. Competitive Landscape

- 3M Pharmaceuticals
- Acrux
- Agile Therapeutics
- Allergan
- ANI Pharmaceuticals
- Antares Pharma
- Bayer HealthCare Pharmaceuticals
- Chase Pharmaceuticals
- Corium International
- DURECT Corporation
- Endo Pharmaceuticals
- Fempharm
- Hisamitsu Pharmaceutical
- Immune Pharmaceuticals
- Imprimis Pharmaceuticals
- Ipsen Bioscience
- Johnson & Johnson
- LaSalle Laboratories
- Lavipharm-increase
- MINRAD International
- NeurogesX
- Novartis
- Noven Pharmaceuticals
- NuPathe
- Nuvo Research
- Pain Therapeutics
- ProStrakan
- Purdue Pharma
- Sanofi
- Scilex Pharmaceuticals
- Senju Pharmaceutical
- Somerset Pharmaceuticals
- Teikoku Seiyaku
- Therapeutic Discovery Corporation
- Transdermal Delivery Solutions
- UCB
- Xel Pharmaceuticals
- Zosano Pharma

For more information visit http://www.researchandmarkets.com/research/gd992k/us_transdermal

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Clinical Trials, Transdermal and Transmucosal Drug Delivery